These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9040725)

  • 21. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
    Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
    Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's Disease.
    Reich SG; Savitt JM
    Med Clin North Am; 2019 Mar; 103(2):337-350. PubMed ID: 30704685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
    Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L
    Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study.
    Williams DR; Lees AJ
    Lancet Neurol; 2005 Oct; 4(10):605-10. PubMed ID: 16168928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dementia with Lewy bodies--from its finding to the present, including the CDLB guideline-revised].
    Kosaka K
    Rinsho Shinkeigaku; 2007 Nov; 47(11):703-7. PubMed ID: 18210780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lewy body disease.
    Hansen LA; Galasko D
    Curr Opin Neurol Neurosurg; 1992 Dec; 5(6):889-94. PubMed ID: 1467583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease.
    Zheng K; Heydari B; Simon DK
    Arch Neurol; 2003 May; 60(5):722-5. PubMed ID: 12756136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic medication unrelated myoclonus is less related to tremor in idiopathic Parkinson's disease.
    Sifoglu A; Gunduz A; Kiziltan G; Kiziltan ME
    Neurol Sci; 2017 Apr; 38(4):679-682. PubMed ID: 27990561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?
    Wenning GK; Ben-Shlomo Y; Hughes A; Daniel SE; Lees A; Quinn NP
    J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):434-40. PubMed ID: 10727478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The patient's perspective: The effect of levodopa on Parkinson symptoms.
    Zach H; Dirkx M; Pasman JW; Bloem BR; Helmich RC
    Parkinsonism Relat Disord; 2017 Feb; 35():48-54. PubMed ID: 27919585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients.
    Ditter SM; Mirra SS
    Neurology; 1987 May; 37(5):754-60. PubMed ID: 3033544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease.
    Sung YH; Chung SJ; Kim SR; Lee MC
    Mov Disord; 2008 Jan; 23(1):137-40. PubMed ID: 17987649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Features in essential tremor and the development of Parkinson's disease vs. parkinsonism.
    Lau HL; Marmol SE; Margolesky J
    Neurol Sci; 2020 Nov; 41(11):3249-3253. PubMed ID: 32394273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diffuse Lewy body disease].
    Kosaka K
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1455-6. PubMed ID: 8752428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and neuropathological findings in Lewy body dementias.
    Galasko D; Katzman R; Salmon DP; Hansen L
    Brain Cogn; 1996 Jul; 31(2):166-75. PubMed ID: 8811993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
    Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
    J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and cognitive profiles of patients with both Parkinson's disease and essential tremor.
    Ozen Barut B; Gunal DI; Turkmen C; Mollahasanoğlu A; Ankaralı H
    Acta Neurol Belg; 2013 Jun; 113(2):117-25. PubMed ID: 22926528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid angiopathy in diffuse Lewy body disease.
    Wu E; Lipton RB; Dickson DW
    Neurology; 1992 Nov; 42(11):2131-5. PubMed ID: 1436523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive supra-nuclear palsy: frequency of cardinal extrapyramidal features at first presentation.
    Pradhan S; Tandon R
    Postgrad Med J; 2015 May; 91(1075):274-7. PubMed ID: 25964368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.